Blood markers may predict ibrutinib success in tough leukemia
NCT ID NCT02827617
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study followed 56 people with a high-risk form of chronic lymphocytic leukemia (CLL) who were taking the drug ibrutinib. Researchers looked for changes in the blood that could show early on whether the drug was working or failing. The goal is to find simple markers that help doctors make better treatment decisions for this hard-to-treat cancer.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Ibrutinib
What this could lead to
If successful, this could help doctors identify early which patients benefit from ibrutinib and which might need a different treatment.
What could go wrong
This is a small, observational study that does not test a new treatment. The findings may not change practice without larger trials.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC LYMPHOCYTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Clinica Ematologica, Centro Trapianti e Terapie Cellulari "Carlo Melzi"
Udine, 33100, Italy
-
Clinica Luganese Moncucco
Lugano, 6903, Switzerland
-
Department of Haematology, Tor Vergata Hospital
Rome, 00133, Italy
-
Department of Medical and Surgical Sciences, section of Hematology
Modena, 41124, Italy
-
Dipartimento di Ematologia, Niguarda Cancer Center, Ospedale Niguarda
Milan, 20133, Italy
-
Division of Hematology, Department of Internal Medicine, Basel University Hospital
Basel, 4031, Switzerland
-
Divisione di Ematologia, Universita' del Piemonte Orientale
Novara, 28100, Italy
-
Ematologia, Ospedale di Circolo e Fondazione Macchi
Varese, 21100, Italy
-
Hematology, Luzern Kantonsspital
Lucerne, 6000, Switzerland
-
Institute of Hematology, Catholic University S. Cuore
Roma, 00168, Italy
-
Onco Ematologia Clinico Sperimentale, I.R.C.C.S. Centro di Riferimento Oncologico
Aviano, 33081, Italy
-
Oncology Institute of Southern Switzerland
Bellinzona, Switzerland, 6500, Switzerland
-
Ospedale San Raffaele
Milan, 20132, Italy